BSE filing, NSE: PARMCOS-B. Summary written from the filing by ALFA Finder's alert engine.
Paramount Cosmetics (I) Ltd: key numbers
- Share price
- ₹37.18
- Market cap
- ₹18.05 Cr
- Revenue (annual)
- ₹21.39 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- 81.7×Sector 38.3×
- Promoter holding
- 74.78%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Paramount Cosmetics (I) Ltd
All →Paramount Cosmetics (I) Board Meeting Date
Paramount Cosmetics (India) Limited intimated a board meeting on 05 Nov 2026 to consider unaudited standalone half-yearly financial results for the period ended September 2026. Trading window closes 01 Oct to 08 Nov 2026.
Paramount Cosmetics (I) Fund Raise of ₹72 Cr
Paramount Cosmetics board approved a rights issue to raise up to Rs.72 crore from existing shareholders. The move strengthens the company's equity capital base.
- Value
- ₹72.00 Cr
Paramount Cosmetics (I) Board Meeting Date
Paramount Cosmetics (India) Limited scheduled a board meeting for October 12, 2026, to discuss other business. Trading window remains closed until November 18, 2026.
Paramount Cosmetics (I) Other Announcement
Paramount Cosmetics India Ltd filed its quarterly shareholding pattern under Regulation 31, disclosing the distribution of equity shares among promoters, public, and other categories.
Paramount Cosmetics (I) Annual General Meeting
Paramount Cosmetics (India) Limited held its 41st Annual General Meeting on September 30, 2026. Shareholders considered the adoption of FY26 financial statements and a material related party transaction.
Paramount Cosmetics (I) Capital Structure Change
Paramount Cosmetics announced increasing authorized share capital from ₹5 crore to ₹39 crore. Shareholders will vote on this proposal at an EGM on October 29, 2026.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr